Background
==========

Hypoglycaemia is an important complication of severe *Plasmodium falciparum*malaria, particularly in children and pregnant women. The prevalence of hypoglycaemia appears to vary in different parts of the world and in different age groups ranging from 8% in SE Asian adults \[[@B1]\] to 10-20% in African children \[[@B2]-[@B5]\]. Hypoglycaemia in children is independently associated with poor outcome \[[@B6]-[@B8]\] and an increased mortality \[[@B2],[@B9]-[@B11]\] predominantly when accompanied by acidaemia (pH \< 7.3) or hyperlactataemia (lactate \> 5 mmol/l) \[[@B12],[@B13]\].

Hypoglycaemia occurs both on presentation to hospital and during the course of admission in children with severe malaria. The aetiology is incompletely understood and is likely to be multifactorial. Depletion of glucose stores due to starvation, parasite utilisation of glucose, cytokine-induced impairment of gluconeogenesis have been implicated \[[@B14]\]. Hyperinsulinaemia, secondary to quinine therapy, has been advanced as an iatrogenic cause and is well established in adults \[[@B15],[@B16]\]. Data on its relationship in African children with severe malaria are relatively few, but what does exist indicates that hyperinsulinaemia rarely accompanies hypoglycaemia either at admission or during quinine treatment \[[@B3],[@B17]\]. However, considerable concern still exists and intravenous dosing is strongly recommended in solutions containing dextrose to avert the risk of hypoglycaemia\[[@B18]\].

There have been no studies that have explored dose dependency of quinine and the occurrence of hypoglycaemia. In 2006, Kilifi District Hospital (KDH) adopted the new World Health Organization (WHO) guidelines for parenteral quinine treatment of severe falciparum malaria, which recommended 20 mg/kg loading dose of quinine followed by 10 mg/kg 8-hourly \[[@B18]\]. Our previous regime, based on pharmacokinetic studies by Winstanley et al \[[@B19],[@B20]\], initiated treatment with a 15 mg/kg loading dose followed by 10 mg/kg twice daily had been in used since 1998. The objective of this study was to examine the relationship of quinine dosage and occurrence of hypoglycaemia by examining the frequency of hypoglycaemia in children treated with either of the two regimes. We investigated clinical events and factors temporally associated with the development of hypoglycaemia during the course of admission.

Methods
=======

The study entailed a retrospective review of case notes for two groups of children (0-12 years) with severe malaria admitted to the paediatric high dependency unit (HDU) of Kilifi District Hospital that is run by Kenya Medical Research Institute/Wellcome Trust Programme, Kenya. All paediatric admissions have a standard admission proforma completed and baseline laboratory investigations. All children presenting for admission to hospital, are triaged, to identify those with life-threatening complications and those who comply with the definition of severe malaria are promptly transferred following stabilisation to our high dependency unit. Parental consent for clinical descriptive surveillance or audit is obtained for all infant paediatric admissions. Ethical approval for ongoing surveillance has been granted by the Kenya Medical Research Institute (KEMRI) ethics committee. The case notes of unselected children fulfilling strictly-defined criteria for severe malaria (*P. falciparum*parasitaemia plus impaired consciousness and/or respiratory distress)\[[@B6]\] were reviewed for this study. Impaired consciousness was defined as Blantyre coma score (BCS) \< = 2, or prostration (inability to breast feed if \< 9 months, or inability to sit unsupported if \> = 9 months). Respiratory distress identified children with deep \'Kussmaul\' breathing, a clinical feature of metabolic acidosis and an independent risk factor for fatal outcome \[[@B6]\]. Mid Upper Arm circumference (MUAC) \< 12 cm, visible severe wasting and/or the presence of oedema (defining kwashiorkor) were used to pragmatically identify the malnourished children \[[@B21]\]. Two time periods were considered: April 2002 - April 2006 cohort which included 954 children treated with the previous quinine regimen (15 mg/kg intravenous loading dose and a maintenance dose of 10 mg/kg 12-hourly) diluted in 5% dextrose and infused intravenously over 2 hours; and May 2006 - July 2009 cohort which included 283 children treated with the new WHO recommended quinine regimen (20 mg/kg intravenous loading dose and a maintenance dose of 10 mg/kg 8-hourly) diluted in 5% dextrose and infused intravenously over 4 hours. Quinine used in both periods was obtained from a single supplier (Indus Pharma Ltd, Pakistan) together with their respective certificates of analysis for each batch.

Standard treatment included intravenous maintenance fluids (5% dextrose and 0.18% saline at 4 mls/kg/hour), intravenous quinine, and antibiotics. Appropriate treatment was started immediately after admission. This current study did not include any child admitted to the general ward with malaria parasitaemia who deteriorated after admission fulfilling the definition of severe malaria, albeit relatively few. Parenteral drugs and intravenous fluids were prescribed until the child was able to take and retain oral fluids and medication. Oral anti-malarial medication prescribed depended on the national treatment policy at the time and included sulfadoxine pyrimethamine (2002-2005) or artemether-lumefantrine (2006-2009). At admission blood glucose was measured in the laboratory using an automated glucose oxidase system (Analox instrument (Analox(r) London, UK)). Thereafter blood glucose was routinely monitored using the bedside monitoring device Accu-Chek™ Advantage (Roche diagnostics, Sydney, Australia; precision of 0.1 mmolL) at one hour post admission and four-hourly until cessation of quinine. Hypoglycaemia, defined as a blood glucose less than or equal to 3 mmol, determined by either device, was managed with an intravenous bolus of 5 ml/kg of 10% dextrose which has been the standard of care in the HDU since 2000 \[[@B18]\]. Additional measurements were conducted during episodes of seizure or posturing activity, transfusion or clinical deterioration. The Accu-Chek™ machine was calibrated weekly and every time a new box of test strips was opened.

In-patient medical and nursing case notes and observation charts for all children admitted with severe malaria over the period of the study were reviewed to identify and confirm episodes of hypoglycaemia (capillary or venous blood glucose equal or less than 3.0 mmol/l) that occurred post-admission and therefore after commencement of parenteral quinine. Clinical events occurring around each hypoglycaemia episode (4 hrs before and one hour after the episode) were examined and recorded. We also examined the frequency of hypoglycaemia cases for three different definition thresholds; \< 2.2 mmol/l (severe hypoglycaemia), \< 2.5 mmol/l (moderate hypoglycaemia), and \< = 3 mmol/l (any hypoglycaemia). In clinical practice different blood glucose thresholds are used to define hypoglycaemia. Studies have shown that hypoglycaemia \< 2.2 mmols/L is associated with poor outcome \[[@B22]\] and this complication is incorporated within the case definition of severe malaria in children and adults \[[@B23]\]. International paediatric guidelines recognize a blood glucose of \< 3 mmols/L, in children with severe disease as a therapeutic indication for treatment \[[@B24]\]. We adopted this practice in 2002 for all severely ill children. The WHO guidelines, on the other hand, recommends \< 2.5 mmol/l threshold for treatment of hypoglycaemia in children with severe illness \[[@B18]\].

There was incomplete data on the prevalence of neurological sequelae after discharge and therefore this data was not included.

Statistical analysis
--------------------

Baseline characteristics were compared between the two groups (regimens). Proportions were compared for categorical variables using Chi-square tests and Fisher\'s exact where appropriate. Malaria parasitaemia was summarised as a geometric mean \[95% reference range\]. For continuous variables, Student\'s t-test was used to compare mean differences between the two regimens. In any case of non-normal data, Mann Whitney (Wilcoxon Rank sum) test was used to make comparison between the two groups. Relative risk of hypoglycaemia in the two treatment groups was also estimated. Clinical definitions of severity features and our definition of circulatory collapse (hypovolaemic shock) have been described previously \[[@B13],[@B23]\]. Variables with clinical plausibility or that were imbalanced at baseline between the two groups were chosen for univariable analysis to test association with post-admission hypoglycaemia. Those variables with p-values ≤ 0.15 were chosen for inclusion in the multivariable logistic regression to adjust for confounding. Variables were adjusted for age in the multiple regression analysis. The regression model was tested for specification error and goodness of fit. Significance was evaluated at 5% level. Analysis was done using Stata version 11 (Stata corporation, Texas, United States).

Results
=======

A total of 954 children were treated with the old regimen (April 2002 to April 2006) and 283 children were treated with the new regimen (May 2006 - July 2009). Male children comprised 50% of cases in both cohorts. Children treated with the old regimen cohort were younger, median age 28 months (IQR 18 - 43) compared to the new regimen 36 months (IQR 25 - 48), p \< 0.01. Detailed admission characteristics for the children in two cohorts are shown in Table [1](#T1){ref-type="table"}. Children in the 2006-2009 cohort had higher parasitaemia but a lower proportion of severity indicators (coma, deep breathing, severe anaemia and hypoglycaemia) than the 2002- 2006 cohort (Table [1](#T1){ref-type="table"}). Severe hypoglycaemia (\< 2.2 mmols/L) was also more common at admission in the 2002-2006 cohort than in the 2006-2009 cohort: 119 (12%) versus 19 (7%) (p = 0.007), respectively.

###### 

Admission characteristics for children in the two cohorts

  Clinical features                         Quinine 15 mg/kg (N = 954) n (%)   Quinine 20 mg/kg (N = 283) n (%)   P-value ^Ŧ^
  ----------------------------------------- ---------------------------------- ---------------------------------- -------------
  Coma (BCS ≤ 2)                            434/953 (46)                       123/279 (44)                       0.67
  Deep breathing                            391/953 (41)                       95/277 (34)                        0.04
  Impaired consciousness                    706/953 (74)                       204/279 (73)                       0.91
  Severe anaemia (Hb \< 5 g/dl)             229/949 (24)                       47/279 (17)                        0.01
  Temperature gradient                      263/951 (28)                       55/277 (20)                        0.009
  Delayed capillary refill (\> 2 seconds)   232/953 (24)                       41/279 (15)                        0.001
  Weak Pulse volume                         159/953 (17)                       31/277 (11)                        0.03
  Mid Upper Arm Circumference \< 12 cm      59/914 (6)                         9/240 (4)                          0.11
  Visible wasting                           58/953 (6)                         6/277 (2)                          0.01
  Seizures                                  168/953 (18)                       38/277 (14)                        0.13
  Prostration                               436/953 (46)                       104/279 (37)                       0.05
  Hypoglycaemia \< = 3 mmol/l               155/952 (16)                       26/282 (9)                         0.003
  Severe hypoglycaemia(\< 2.2 mmol/l)       118/952 (12)                       19/282 (7)                         0.008
  Creatinine \> 80 mmol/l                   225/904 (25)                       49/211 (23)                        0.61
  Potassium \> 5 mmol/l                     149/934 (16)                       17/259 (7)                         \< 0.01
  **Mean laboratory variable \[SD\]**                                                                             
  Haemoglobin level, mg/dl                  7.06 \[2.63\]                      7.53 \[2.44\]                      0.004
  pH                                        7.28 \[0.14\]                      7.30 \[0.51\]                      0.34
  pCO~2~,mmol/L                             4.17 \[1.92\]                      3.98 \[1.73\]                      0.18
  Base Deficit, mmol/L                      9.99 \[6.63\]                      8.49 \[5.72\]                      0.002
  Sodium level, mmol/l                      134.33 \[5.62\]                    133.39 \[5.51\]                    0.02
  Creatinine level, mmol/l                  68.89\[41.7\]                      66.81 \[32.65\]                    0.49
  Parasitaemia ×10^3^parasites/μl           3651 \[3149 - 4234\]               5604 \[4393 - 7150\]               0.01

IQR - Inter-quartile range, SE-Standard error, ^Ŧ^Test statistic - χ^2^test or t-test on means

Frequency of hypoglycaemia post admission
-----------------------------------------

Fifteen percent (145/954) of the 2002-2006 cohort developed hypoglycaemia (\< = 3 mmols/l) post admission as did 15% (42/283) of the 2006-2009 cohort OR = 0.97, 95% confidence interval \[0.67-1.41\]; P = 0.88. The prevalence of hypoglycaemia, if compared with baseline levels, increased overall by 6% (from 9% at admission) in the 2006-2009 cohort, but decreased by 1% in the 2002-2006 cohort post admission (from 16% at admission). Of the 145 children in the 2002-2006 cohort who developed hypoglycaemia after treatment, 103 (71%) were euglycaemic at admission and 42 (29%) had hypoglycaemia at baseline. Sixty eight percent (99/145) of these children had a single episode and 46 (32%) had multiple episodes. Of the 42 children in the 2006-2009 cohort who developed hypoglycaemia after treatment, 27 (66%) were euglycaemic at admission whilst 14 (34%) had hypoglycaemia at admission. Fifty two percent (22/42) of the children had a single episode whilst the remaining 20 (48%) had multiple episodes. Overall, children presenting with hypoglycaemia at admission had increased odds of having an episode post admission, OR = 3.18 (CI 2.21 - 4.58, p \< 0.0001). For children who were euglycaemic at admission there was no statistical difference in frequency of subsequent episodes between the two cohorts (p = 0.32). When comparing the numbers with multiple episodes of hypoglycaemia post admission between the two cohorts, there was weak evidence of a slight increase during the new regime (p = 0.06). Figure [1](#F1){ref-type="fig"} shows the frequency of single and multiple episodes in the two cohorts.

![**Frequency of episodes in the two cohorts: Quinine 15 mg/kg n = 145, Quinine 20 mg/kg n = 42**.](1471-2334-10-334-1){#F1}

Timing and distribution of hypoglycaemia episodes
-------------------------------------------------

The distribution and timing of hypoglycaemia episodes was explored and the results are shown on Table [2](#T2){ref-type="table"}. We found no statistical difference in the timing of the events between the two cohorts (χ^2^for trend, p = 0.15) although the children who developed hypoglycaemia receiving the new regimen (2006-2009 cohort) had a higher proportion of the first episode occurring after 24 hours (OR: 0.57; 95% CI: \[0.26 - 1.24\]).

###### 

Time of occurrence of first hypoglycaemia episode and hypoglycaemia severity

                                                                                                               2002-2006 cohort: Quinine 15 mg/kg regimen   2006-2009 cohort: Quinine 20 mg/kg regimen              
  ------------------------------------------------------------------------------------------------------------ -------------------------------------------- -------------------------------------------- ---------- ---------
  0 - 24 hrs                                                                                                   118 (81)                                     157 (69)                                     30 (71)    47 (55)
  After 24 hrs                                                                                                 19 (13)                                      41 (18)                                      6 (14)     21 (24)
  After 48 hrs                                                                                                 8 (6)                                        31 (14)                                      6 (14)     18(21)
  **Severity (Blood glucose levels), n/N (%)**                                                                                                                                                                      
  \< 2.2 mmol/l                                                                                                74/954 (8)                                   13/283(5)                                    P = 0.07   
  \< 2.5 mmol/l                                                                                                103/954 (11)                                 22/283(8)                                    P = 0.14   
  \< = 3.0 mmol/l                                                                                              145/954 (15)                                 42/283(15)                                   P = 1.00   
  **Final outcome (death) - those with and those without any hypoglycaemia post admission, n/N (%)**                                                                                                                
  Hypoglycaemia = Yes                                                                                          29/145 (20)                                  15/42 (36)                                   P = 0.04   
  Hypoglycaemia = No                                                                                           73/809 (9)                                   13/240 (5)                                   P = 0.07   
  **Final outcome (death) - those with and those without any hypoglycaemia at or during admission, n/N (%)**                                                                                                        
  Hypoglycaemia = Yes                                                                                          45/155 (29)                                  11/26 (42)                                   P = 0.18   
  Hypoglycaemia = No                                                                                           57/797 (7)                                   17/255 (7)                                   P = 1.00   

Severity of Hypoglycaemia
-------------------------

Using the strict definition for severe hypoglycaemia (\< 2.2 mmol/l) a lower proportion of children developed profound hypoglycaemia, 13/283 (5%) on the new regimen group compared to the old regimen group (2002-2006 cohort), 74/954 (8%) (OR: 0.57; 95% CI: \[0.32 - 1.04\], P = 0.07). Using a slightly less stringent threshold (\< 2.5 mmol/l) we found little difference in the numbers developing hypoglycaemia (22/283, 8%) on new regimen compared to (103/954, 11%) on the old regimen (OR: 0.70; 95% CI: \[0.43 - 1.12\], P = 0.14). Table [2](#T2){ref-type="table"} summarises the distribution and severity of the episodes of hypoglycaemia post admission and Figure [2](#F2){ref-type="fig"} shows the frequency of hypoglycaemia using the different cut-offs in the two cohorts.

![**Frequency of hypoglycaemia severity using different definitions**. The x-axis includes blood sugar thresholds of \< = 3 mmols/L, 2.5 mmols/L and \< 2.2 mmols/L](1471-2334-10-334-2){#F2}

Mortality and Clinical associations
-----------------------------------

In-hospital case fatality was similar in the respective cohorts, 102/954 (11%) and 28/283 (10%) (χ^2^= 0.13, p = 0.71). For both cohorts the development of any episode of hypoglycaemia (\< = 3 mmols/L) after admission was associated with an increased odds of dying when compared to those who remained euglycaemic, 44/187 (24%) and 86/1049 (8%) respectively, OR = 3.45 (95% confidence interval = 2.30-5.16), (P \< 0.01).

Clinical events concurring with episodes of hypoglycaemia in both cohorts included coma (defined as BCS \< = 2) in 57% of the episodes; evidence of circulatory failure (hypovolaemic shock) in 38% of episodes; 21% were associated with clinical features of metabolic acidosis (deep breathing). In addition, 24% (45/187) of episodes occurred during a blood transfusion whilst 37% (70/187) of the episodes occurred during a period of inadequate glucose supply (accidental or actual discontinuity of intravenous maintenance glucose). Episodes of seizures and/or posturing were less frequently associated with hypoglycaemia; they were co-incident in 10% and 9% of the hypoglycaemia episodes, respectively. Our preliminary exploration of the data which examined only the first episode of hypoglycaemia (\< = 3 mmols/L) after admission indicated little differences in the frequency of these associated clinical factors between the two cohorts.

Predictors of hypoglycaemia post admission
------------------------------------------

In the age-adjusted analysis of the predictors of hypoglycaemia post admission, the following factors were associated with increased risk of developing hypoglycaemic post admission: hypoglycaemia at admission, deep breathing, severe anaemia, temperature gradient (a sign of impaired perfusion and pragmatically assessed by running the back of the hand from the foot up the shin: where the foot was cooler than the shin this indicates a temperature gradient) and weak pulse volume (an advanced sign of hypovolaemic shock) (Table [3](#T3){ref-type="table"}). Multivariable logistic regression was used to adjust for variables that were predictive in the univariable analysis (variables with p values \< 0.15). The following variables were significant predictors of hypoglycaemia post admission at multiple regression analysis: hypoglycaemia at admission, severe anaemia and temperature gradient (all adjusted for age in months).

###### 

Predictors of Hypoglycaemia post admission

                                      Univariable analysis   Multiple regression analysis                          
  ----------------------------------- ---------------------- ------------------------------ ---------------------- ----------
  **Treatment:Regimen**               0.97 \[0.67 - 1.41\]   0.88                           \-                     \-
  **Hypoglycaemia at admission**      3.18 \[2.21 - 4.58\]   \< 0.001                       2.76 \[1.87 - 4.06\]   \< 0.001
  **Deep breathing**                  1.46 \[1.06 - 1.99\]   0.02                           0.96 \[0.67 - 1.36\]   0.80
  **Severe anaemia**                  1.91 \[1.36 - 2.69\]   \< 0.001                       1.57 \[1.08 - 2.29\]   0.02
  **Temperature Gradient**            2.10 \[1.51 - 2.92\]   \< 0.001                       1.77 \[1.22 - 2.57\]   0.003
  **Delayed Capillary refill time**   1.63 \[1.15 - 2.31\]   0.006                          1.00 \[0.65 - 1.55\]   0.98
  **Visible wasting**                 1.78 \[0.98 - 3.25\]   0.06                           1.32 \[0.69 - 2.54\]   0.40
  **Prostration**                     0.88 \[0.64 - 1.20\]   0.41                           \-                     \-
  **Weak pulse volume**               1.63 \[1.11 - 2.41\]   0.01                           0.93 \[0.58 - 1.49\]   0.75
  **Parasitaemia^\#^**                1.29 \[0.86 - 1.95\]   0.22                           \-                     \-

\*Adjusted for age in months; OR - Odds ratio; CI - Confidence Interval.

Treatment, prostration and parasitaemia not included in the multivariable model as p \> 0.15

^\#^Parasitaemia was categorised as below or above 5000 parasites/microlitre

Discussion
==========

Despite some recent and localized successes in disease control severe malaria remains a major public health burden in sub Saharan Africa killing over half million children each year \[[@B23]\]. Parenteral quinine is therefore one of the most widely used treatment in African hospitals and information about the potential iatrogenic side effects remain pertinent. Our study provides valuable information for clinicians treating children with severe malaria in Africa with respect to the occurrence of life-threatening hypoglycaemia and its clinical associations. Hypoglycaemia occurs in 15% of children following admission, with over 70% of episodes occurring within 24 hours of admission. We found no evidence of a dose-response relationship between quinine and any degree of hypoglycaemia after admission. The most important clinical variables at admission that predicted development of hypoglycaemia after admission were hypoglycaemia, severe anaemia and temperature gradient (a marker of impaired perfusion or circulatory failure). Most episodes were single events and frequently concurrent with one or more markers of disease severity including coma, clinical features of impaired perfusion, deep breathing (Kussmaul breathing) but less commonly associated with the time-honoured suspected clinical associations of seizures or posturing. We found a coincidence of hypoglycaemic episodes during transfusions or periods of disruption of intravenous glucose infusion. Overall, fatal outcome was more common in children developing hypoglycaemia after admission than their euglycaemic counterparts.

Our previous regime, based upon pharmacokinetic studies, indicated that lower doses were warranted due to a smaller apparent volume of distribution in the children, and that a higher dosage regime was justifiable for adults and in areas where quinine-resistance was more problematic \[[@B19]\]. A recent large trial in Asia (SEQUAMAT) showed that parenteral artesunate reduced mortality by 35% compared to conventional quinine treatment \[[@B25]\]. SEQUAMAT, together with previous studies, have shown a lower frequency of hypoglycaemia in the artesunate treated group \[[@B26]-[@B29]\]. Our data, and that of previous studies, do not suggest any dose- dependent relationship with quinine treatment in African children with severe malaria. For this and many other reasons a separate trial in African children is underway (AQUAMAT ISRCTN 50258054).

Hypoglycaemia remains a common complication of severe malaria, occurring throughout the clinical course. The origin, in African children, is unlikely to be iatrogenic. Studies comparing children with severe malaria and other severe illnesses found no difference in the frequency of this complication, indicating that it is a consequence of multi-organ involvement manifest in severe life-threatening illness \[[@B11]\]. Plasma glucose concentration reflects the balance between glucose supply and glucose use in children with severe illness including malaria. Inadequate glucose supply and fasting have been implicated in a number of studies in children with severe malaria \[[@B11],[@B30]\] but others examining glucose kinetics conclude that gluconeogenesis and endogenous glucose production is preserved or even increased \[[@B28],[@B31]\] but glucose supply however, is disproportionately derived from glycogenolysis. Zijlmans and colleagues recently demonstrated that even after 16 hours of fasting glycogenolysis contributed to 35-40% of the glucose production \[[@B32]\]. This finding is surprising given that it had been previously assumed that the glycogen stores in young children are believed to support a maximum fasting period of 12 hours \[[@B33]\]. In our study we found that discontinuation of a 5% glucose infusion either prematurely in a fasting child, during a transfusion or accidentally (non-patency of an intravenous cannula) was one of the events that were commonly observed in association with hypoglycaemia. Nutritional status is an important determinant of glycogen stores, which may be critical in a severely ill child. Most of our cohort had mild to moderate undernutrition, with the median weight for height or length z-score (WHZ-score) -1.5 \[IQR (-2.4, -0.65)\], which may explain why fasting was associated with early hypoglycaemia (within the four hours period of the event) and at variance with the studies in Surinamese children, whose median WHZ-score was 0.6 \[[@B32]\]. These observations concur with our earlier studies indicating that whilst glucose production is increased in severe malaria it fails to compensate to the increased demand and therefore puts children at risk of developing hypoglycaemia \[[@B30]\]. For children receiving blood transfusion, which ought to contain adequate dextrose/citrate to prevent hypoglycaemia, either the stress of transfusion or relative inadequacy of glucose supply may lead to a higher risk of hypoglycaemia in a severely ill child. Whilst inappropriate transfusions should be discouraged we strongly recommend additional glucose monitoring of children receiving blood transfusion.

The characteristic clinical manifestations of hypoglycaemia are rarely evident owing to disease severity and careful monitoring is recommended to facilitate early diagnosis and prevent poor outcome and neurological sequelae \[[@B34]-[@B36]\]. There is need for more evidence from randomised trials to define the ideal threshold for treatment of hypoglycaemia as recent observational studies have shown that mortality is still higher at a threshold greater than 3.0 mmol/l. A recent review by Achoki and colleagues demonstrated in a prospective cohort study of all paediatric admissions that blood glucose concentrations at admission of up to 4.0 mmol/l was associated with increased odds of mortality compared to all levels of glucose concentration above this threshold \[[@B37]\]. Another recent study conducted in Mali by Willcox and colleagues demonstrated that low glycaemia (2.2-4.4 mmol/l) was significantly associated with odds of mortality in children with a clinical diagnosis of severe malaria \[[@B38]\]. The authors concluded that the optimum threshold is 6.1 mmol/l for predicting mortality which is much higher than current definitions.

Our study has a number of limitations. First, the retrospective design, rather than a randomised trial, meant that the two study cohorts were not identical in terms of overall disease-severity indices. The children in the 2006- 2009 cohort were on average older, had fewer severity indicators at admission but survival was similar in the two groups. The clinical associations with hypoglycaemia after admission were identical and reassuringly the occurrence of severe hypoglycaemia was less apparent in the latter cohort. Secondly, glycaemic control was monitored using bedside handheld glucometers. The performance of point of care devices in accurately determining hypoglycaemia has been questioned \[[@B39]\], since they have been associated with underestimation of hypoglycaemic events, particularly in patients with moderate to severe anaemia. Recent studies have demonstrated that moderate to severe anaemia explains most of the major variance between glucometer and quality control laboratory readings \[[@B40]\]. For patients with a haematocrit below 20 the percentage error of glucometer measurements, compared to the reference laboratory glucose, was nearly 30% \[[@B40]\]. In our study, monitoring was largely by hand held devices, although this may have introduced a systematic error in glucose readings, the glucometers used in both cohorts were identical and therefore unlikely to have biased the comparison. Another limitation was the unequal numbers in the two cohorts. There were fewer cases of severe malaria in the 2006 - 2009 cohorts and this reflects the changing trend in malaria epidemiology in the study area \[[@B41]\].

Conclusions
===========

We found no relationship between quinine dosage and the frequency or severity of hypoglycaemia in African children with severe malaria. Overall 15% of children with severe malaria developed hypoglycaemia after admission most commonly on the day of admission. Hypoglycaemia occurrence was temporally associated with markers of disease severity and disruption in the maintenance glucose supply. Owing to the poor outcome a case fatality of 24% compared to 8% in euglycaemia children indicate the need for targeted glucose monitoring in children who remain severely ill and prevent premature termination of glucose maintenance infusion. Further research, including controlled trials, to establish best practice is urgently needed.

Competing interests
===================

The authors declare that they have no competing interests.

Authors\' contributions
=======================

GO, SA and KM - conceived and designed the study, acquisition of data, data analysis, drafting the manuscript and interpretation of data. JJ, GF - study design, data analysis, drafting the manuscript and interpretation of the data. MB and EK- conceived and designed the study, acquisition of data and interpretation of data. All the authors read and approved the final manuscript.

Pre-publication history
=======================

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2334/10/334/prepub>

Acknowledgements
================

The authors acknowledge the support and assistance from the following persons; Eric Ohuma, for statistical assistance, Kilifi District Hospital paediatric High dependency unit staff, data archiving staff (Josephine and Ramos) and data management staff.

**Funding Source:**KEMRI-Wellcome Trust Programme received a Wellcome Trust Major Overseas Award to support its core scientific activities (Grant Number 077092). SA is supported by a grant from the Wellcome Trust; 084538. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
